Introduction
In recent years macromolecules associated with fetal growth have been recognized with increasing frequency in association with a variety of different tumours in adults (Gold and Freedman, 1965; Tee et al., 1965; Yashi et al., 1968; Haakinen and Viikari, 1969; Barnes and Tee, 1970; Buffe et al., 1970; Edynak et al., 1970; Abelev, 1971; Klavins et al., 1971; Trouillas, 1971; Purves and Geddes, 1972) and particular attention has been paid to their possible role in the diagnosis and treatment of neoplasms. They have usually been detected by immunological methods which have involved raising antisera to them in a heterologous host. For this reason these materials are referred to as fetal antigens, although this does not imply that they are antigenic in the host of origin. The question of terminology is complex and has been discussed by Alexander (1972) . To be of practical clinical value such materials will need to pass from the tumour into the body fluids and to decline in quantity with effective therapy. It is hoped that their presence might serve as an indicator of incipient tumour formation and thereby contribute to earlier and more precise diagnosis.
The carcinoembryonic antigen (C.E.A.) is a glycoprotein that appears to fulfil some of the above criteria. C.E.A. was described initially by Gold and Freedman (1965) in primary adenocarcinomas of the colon but not in autologous, uninvolved colonic mucosa, and it was found also in the embryonic liver, pancreas, and gastrointestinal tract during the first two trimesters of pregnancy. More recent investigations have confirmed these observations (Kleinman et al., 1971; Coligan et al., 1972) and also shown very small amounts to be present in normal adult digestive tract tissues (Martin and Martin, 1970) . With the development of radioimmunoassays for measuring C.E.A. (Thomson et al., 1969; LoGerfo et al., 1971; Egan et al., 1972) it was possible to estimate its quantitative occurrence in body fluids in normal subjects and patients with a variety of neoplastic and nonneoplastic disorders.
While originally raised plasma C.E.A. levels were thought to be specific to endodermal tumours (Thomson et al., 1969) further experience with similar (Moore et al., 1971) and different (LoGerfo et al., 1971) reagents has shown that raised C.E.A. values can occur with a wide variety of non-neoplastic disorders and with neoplasms of differing histogenesis, including neuroblastoma (Reynoso et al., 1972) . In addition, one of the most recent reports suggests that the C.E.A. level in patients with colonic carcinomas may depend on the extent of spread of the tumour (LoGerfo et al., 1972) .
The purpose of this report is to present our attempt to determine the role of plasma C.E.A. assays in the clinical management, diagnosis, and therapeutic monitoring of patients with tumours, particularly of the gastrointestinal tract, breast, and bronchus, and to examine the relation, if any, between the plasma C.E.A. levels and the stage of tumour spread and its degree of structural differentiation. (Table I) ; moreover, the C.E.A. level tended to be lower than that detected with gastrointestinal tumours. The incidence of high C.E.A. levels in benign conditions of the breast was low; none had levels in excess of 40 ng/ml.
Respiratory Disorders.-While a high proportion (66%) of patients with carcinomas of the bronchus and upper respiratory tract had C.E.A. in excess of 12-5 ng/ml (Table I) , high values were often found in patients with inflammatory chest diseases. Examination of the data from patients with pulmonary infections showed that of the 14 patients falling into the false-positive group 10 smoked cigarettes. None of the healthy control group of subjects who smoked cigarettes had levels in excess of 12-5 ng/ml, and of 60 patients with a variety of benign or inflammatory conditions who also smoked cigarettes only 18 had levels over 12-5 ng/ml. The rest had normal values. Thus it may be the combination of chest infection and smoking which is primarily responsible for the raised false-positive levels in such patients.
Miscellaneous.-A variety of neoplastic and non-neoplastic pathological conditions at other sites in the body in which plasma C.E.A. was examined are listed in Table II . With the possible exception of carcinoma of the bladder, where urinary C.E.A. levels can be raised and which is dealt with in detail in Uterus^C arcinoma of endometrium the accompanying paper (Table III) . (LoGerfo et al., 1971) if the cut-off for abnormality is set at 12i5 ng/ml and 2i5 ng/ml respectively. The quantitative differences are probably caused by the presence in unextracted plasma of interfering background substances. Consequently, the present system, by requiring only a small volume (0-2 ml) of plasma and avoiding the time-consuming extraction and concentration procedures, represents a satisfactory alternative more amenable in time to routine clinical applicability than previous techniques (Thomson et al., 1969; LoGerfo et al., 1971; Moore et al., 1971) .
Initially C.E.A. was thought to be an endodermal-specific substance (Gold and Freedman, 1965; Burtin et al., 1971) . Further experience using more sensitive methods, however, has resulted in its detection in normal tissues (Martin and Martin, 1970) , colonic polyps (Burtin et al., 1972) , the plasma of healthy persons and subjects with a variety of tumours of differing histogenesis, and several non-neoplastic disorders (LoGerfo et al., 1971 (LoGerfo et al., , 1972 Moore et al., 1971; Laurence et al., 1972; Reynoso et al., 1972; Zamchek et al., 1972) . Hence C.E.A. is neither endodermal nor tumour-specific and the differences between its occurrence in normal and neoplastic tissues are quantitative rather than qualitative. It is therefore not surprising that high plasma levels occur in association with reactive hyperplastic and benign neoplastic conditions.
The estimation of plasma C.E.A. appears to have most clinical value in patients with gastrointestinal and bronchial carcinomas and neuroblastomas in this (Tables I, III , and IV) and other series (LoGerfo et al., 1971 (LoGerfo et al., , 1972 Reynoso et al., 1972; Zamchek et al., 1972) . This technique at the present time appears to have little, if any, part to play in the clinical evaluation of tumours of the male and female genitalia and adnexae, skin and brain, or in lymphoreticular neoplasia (Table II) . Other tumour-associated antigens have recently been described in Hodgkin's disease (Order et al., 1971) and leukaemia (Viza et al., 1970) but their role in assessing progress and improving diagnosis remains to be evaluated. While the assay of plasma C.E.A. in patients with urothelial carcinoma is of little value, urinary C.E.A. levels are raised in most patients with this disorder. These results are presented in detail in the accompanying communication .
At the outset of our studies there appeared to be three principal clinical applications of plasma C.E.A. estimation. Firstly, it might serve as a screening procedure for the detection of cancer. Secondly, it might aid in the differential diagnosis of neoplastic disorders and, thirdly, be a means of monitoring the effectiveness of therapy and the development of tumour recurrences.
The present methods of estimating C.E.A. may not warrant its use as a preliminary screening test as they will not detect every subject with cancer and will detect many with non-neoplastic diseases. If one accepts the level of 40 ng/ml and above as almost pathognomonic of cancer (Tables I and II) , then only a minority of tumours would be diagnosed early in their course. If all values in excess of 12-5 ng/ml are considered abnormal, then this would result in the detection of about 45% of early primary carcinomas of the colon, rectum, and stomach and about 30% and 60% of early mammary and bronchial carcinomas respectively (Table III) , while including many patients with non-malignant diseases (Tables I and II) . However, we are unable to say that by detecting such a group of subjects in the general or hospital outpatient population, whose plasma C.E.A. levels are raised, and then investigating them in detail lives would not be saved. It may be that a limited trial of its usefulness in a "high-risk" population is still warranted at present.
Neither the cell type nor the degree of structural differentiation of gastrointestinal, mammary, and bronchial carcinomas (Table IV) seems to influence the level of plasma C.E.A., which for most tumours appears to be determined more by the extent of their spread (Table III; LoGerfo et al., 1972; Zamchek et al., 1972) . Disorders such as diverticulitis, peptic ulceration, and ulcerative colitis, which feature prominently in the differential diagnosis of gastrointestinal neoplasia can result in raised C.E.A. levels which, however, do not as a rule exceed 40 ng/ml. In patients with ulcerative colitis and Crohn's disease there does not appear to be any correlation of the C.E.A. level and disease severity. None of these subjects whose C.E.A. level exceed 20 ng/ml had detectable colonic carcinoma despite diligent searches. Consequently it has a very limited, if any, value in the differential diagnosis of gastrointestinal neoplasia. This conclusion also applies to pulmonary disorders. It would have been valuable to have had a test which could have given some indication of the onset of bronchial neoplasia, particularly in an "at-risk" group such as those who smoke cigarettes. With regard to mammary disorders, while the incidence of falsepositive results is very low, the overall positive rate is such that little reliance can be placed on a negative result. However, it may be premature to dismiss the raised values in some patients with ulcerative colitis, chronic bronchitis, or cirrhosis as being falsepositives. High C.E.A. levels have been observed by others in healthy subjects or those with "non-specific" complaints who subsequently developed carcinomas (LoGerfo et al., 1971) . Further sequential studies of these subjects may be warranted.
The most valuable aspect of C.E.A. assay at present may be to monitor therapy and to detect the developmeat of recurrences or tumour spread. We and LoGerfo et al. (1972) found that raised plasma levels decline to normal early in the postoperative period if adequate surgery has been effected. The Recent experimental data have related the metastasizing ability of some tumours to a loss of their surface glycoprotein into the plasma (Kim and Carruthers, 1972) . Consequently it seems important to follow all the subjects of this study with malignant tumours and ascertain if those tumours with high plasma C.E.A. levels pursue a different course and tend to metastasize earlier than those with normal levels.
Chelsea, or the Chelsea Hospital for Women, or who attended a general practitioner's surgery for trivial non-urinary complaints.
Plasma samples were obtained as described previously . Urine was collected in 20 ml sterile containers. No special precautions were taken, in that samples were not midstream nor were they taken at any particular time of the day. Each specimen was tested for albumin, glucose, and blood and for infection or bacterial contamination by means of dip-inoculum plates (Oxoid), which were incubated at 370C for 24 hours. If significant infection (> 100,000 organisms/ml) was found the organisms were identified. Specimens were stored thereafter at -70°C until assay.
Urine samples in 1 ml aliquots were dialysed using cellulose acetate (Visking 8/32) tubing for three hours against phosphatebuffered saline pH 7T2, 0-01 M in EDTA. Duplicate (0-2 ml) samples of the undialysable portion were then assayed for their C.E.A. content as described previously . The results are expressed as ng of C.E.A. per ml of urine.
Results

MALE SUBJECTS
Analysis of the urinary C.E.A. content of healthy control male subjects yielded a mean level of 14 ng/ml, with a coefficient of variation of 1-22. On this basis 35 ng/ml was chosen as the upper limit of normal in males; 42 of the 46 subjects fell below this level (Table I) . None of the four control subjects with raised values had clinical evidence of urinary disease. Examination of the C.E.A. values as a function of age of the control subjects failed to show rising titres with increasing age. Of 30 males with histologically proved active transitional cell carcinomas of the bladder 20 had urinary C.E.A. levels in excess of 35 ng/ml. Fourteen men who had had previously treated carcinomas of the bladder and who at the time of the present study were judged tumour-free cystoscopically and cytologically all had C.E.A. levels within the normal range. Of the seven patients with benign disorders (including peptic ulceration, ulcerative colitis, and urolithiasis) and the 16 with malignant tumours of other systems (including prostate, testis, renal parenchyma, gastrointestinal tract, and skin) only one with colonic diverticulitis and no evidence of urothelial disease had a raised urinary level of C.E.A. Seven of these 16 patients had plasma levels of C.E.A. between 14 ng and 500 ng/ml.
Examination of the high C.E.A. levels given by carcinoma of the bladder according to the clinical stage of the tumour and its
